RT Journal Article
SR Electronic
T1 Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 78
OP 82
DO 10.3899/jrheum.161567
VO 45
IS 1
A1 Leslie R. Harrold
A1 Bradley S. Stolshek
A1 Sabrina Rebello
A1 David H. Collier
A1 Alex Mutebi
A1 Sally W. Wade
A1 Wendi Malley
A1 Jeffrey D. Greenberg
A1 Carol J. Etzel
YR 2018
UL http://www.jrheum.org/content/45/1/78.abstract
AB Objective. Rebound may occur in patients with psoriatic arthritis (PsA) who discontinue TNF inhibitor (TNFi) therapy in low disease activity (LDA).Methods. Using physician and patient reports, we quantified rebound following TNFi discontinuation [defined as Clinical Disease Activity Index (CDAI) score > 10 or TNFi restart] and time to rebound in adults with PsA in LDA (CDAI score ≤ 10) at TNFi discontinuation.Results. Rebound occurred in 73% (69/94) of patients soon after discontinuation (median time to rebound 8.0 mos, 95% CI 6.0–12.0).Conclusion. Rebound occurred frequently in patients with PsA after TNFi discontinuation. TNFi discontinuation after achieving LDA should be carefully considered.